Ceritinib: new treatment for ALK-positive non-small cell lung cancer

Zykadia (ceritinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

Ceritinib is a selective oral ALK inhibitor.  | SCIENCE PHOTO LIBRARY
Ceritinib is a selective oral ALK inhibitor. | SCIENCE PHOTO LIBRARY

Ceritinib inhibits autophosphorylation of ALK, ALK-mediated phosphorylation of downstream signalling proteins and proliferation of ALK-dependent cancer cells both in vitro and in vivo.

Clinical studies

Ceritinib was evaluated in two single-arm studies in patients with ALK-positive NSCLC previously treated with an ALK inhibitor. Investigators used the overall response rate (ORR) as the primary efficacy endpoint.

Further information
View Zykadia drug record
Summary of Product Characteristics
Manufacturer: Novartis

In the first (phase I) study in patients who had previously received treatment with crizotinib (Xalkori) (n=80), the ORR was 56% (95% CI 45–67) and the median progression-free survival (PFS) was 6.9 months (95% CI 5.3–8.8).

The second (phase II) study evaluated the efficacy and safety of ceritinib in 140 patients who had been previously treated with 1-3 lines of cytotoxic chemotherapy followed by crizotinib, and who had then progressed on crizotinib. ORR with ceritinib was 37.1% (95% CI 29.145.7) and median PFS was 5.7 months (95% CI 5.3–7.4).

The most commonly reported adverse effects (≥10%) of ceritinib were GI upset, fatigue, abnormal LFT results, anorexia, raised blood creatinine, rash and anaemia.

Conditional approval

Zykadia has been authorised under the 'conditional approval' scheme, meaning further evidence of clincial benefit from the ongoing second study, as well as a phase III study comparing ceritinib with other chemotherapy, is required. 

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.